Cytek's Borealis launch and a reorg try to rekindle growth — but the patient is still healing
Q2 delivered 6% revenue growth, a new flagship 60-color cytometer, and a guide raise; tariffs provide a one-quarter tailwind while operating losses persist.
CTKB · Earnings Call · 2026-08-05
New products and a new org chart
The second-quarter call was dominated by two things: a flagship product launch and a reorganization. Wenbin Jiang opened with the Cytek Borealis, the industry's first 60-color, 7-laser full spectrum flow cytometer. The launch extends a line of high-end instruments that already delivered mid-teens growth in Q2. He also confirmed that the company is moving to three customer-aligned business units — Solutions & Clinical, Research Technology, and Service. William McCombe said the primary objective is "to align resources around different customer segments" and that the guide already assumes the implementation.“We built upon our good start to the year with continued positive momentum through the second quarter, delivering another period of solid revenue growth.” — Wenbin Jiang, Chief Executive Officer · 2026-08-05
We recently introduced the Cytek Borealis, the industry's first 60-color, 7-laser, full spectrum flow cytometer.
Numbers: a 6% top line, but the profit picture is still thin
Revenue hit $48.1M, up 6% YoY, with US up 18% and China double-digit. Service grew 10%, and recurring revenue rose to 35% of LTM. The gross margin story was dominated by a one-time tariff refund of $2.8M, which pushed GAAP gross margin to 59% (or 53% ex-refund).“For subsequent quarters of this year, we expect gross margins, excluding the impact of the tariff refund, to increase as our revenue increases, consistent with our typical seasonal pattern.” — William McCombe, Chief Financial Officer · 2026-08-05The 60% product gross margin (52% ex-refund) is only marginally better than the 53% last year.Operating loss widened to $11.4M, and net loss was $12.2M on FX losses and a $1.6M write-off. Adjusted EBITDA was negative $1.5M vs +$1.3M a year ago, though the company expects to be around break-even for the full year.
Confluence: tariff refunds are a market-wide theme
Cytek isn't alone in receiving tariff relief. The global tape shows "IEEPA tariff refund" as a 90-day advancer touching names like CAH, BAX, HLIO, MAS, and others. Several recent reporters — from medical devices to industrials — have also cited refunds. This suggests the Q2 boost is a common tailwind, not a company-specific event.
Watch items: the replacement opportunity and the academic rebound
Cytek still sees a large installed base of ~46,000 conventional cytometers as a replacement target. Wenbin noted annual placements of 7,000–10,000 and that customers are "shifting more and more toward full spectrum technology." The U.S. academic/government rebound is a key swing factor; a prior quarter noted "Academic and government in Q1 was up ... substantially on Q1 of last year."“Academic and government in Q1 was up ... substantially on Q1 of last year.” — William McCombe, Chief Financial Officer (CFO) · 2026-05-07Tariff management has been an ongoing theme, with the earlier region-for-region strategy. As Bill said last year, "Our primary strategy for managing tariffs is what we call region-for-region manufacturing."“Our primary strategy for managing tariffs is what we call region-for-region manufacturing.” — William McCombe, CFO · 2025-05-08